目的 探討哌柏西利致不良反應(yīng)的發(fā)生規(guī)律和臨床表現(xiàn)特點，為其臨床安全用藥提供參考。方法 檢索中國知網(wǎng)、萬方數(shù)據(jù)、維普網(wǎng)、PubMed、Web of Science文獻數(shù)據(jù)庫中建庫至2023年12月哌柏西利致不良反應(yīng)案例報道并進行統(tǒng)計分析。結(jié)果 納入文獻40篇，涉及患者44例，均為女性且以60歲以上患者居多；發(fā)生時間為用藥后1 d～15個月，主要集中在前3個月內(nèi)（63.64%）；累及皮膚、呼吸系統(tǒng)、血液系統(tǒng)、神經(jīng)系統(tǒng)等全身多個器官/系統(tǒng)。33例患者經(jīng)停藥和/或?qū)ΠY處理后好轉(zhuǎn)，6例患者死亡，可見其潛在的致死風(fēng)險。結(jié)論 臨床工作者應(yīng)重視哌柏西利致不良反應(yīng)的危害性，加強患者用藥監(jiān)護，確保臨床用藥安全。

Objective To investigate the occurrence pattern and clinical manifestation characteristics of adverse drug reactions caused by palbociclib, and to provide reference for its safe clinical use. Methods Case reports of adverse reactions caused by palbociclib were retrieved from CNKI, Wanfang Data, VIP, PubMed, and Web of Science literature databases from December 2023 and analyzed statistically. Results Forty literatures were included, involving 44 patients, all of whom were female and most of whom were over 60 years old. The occurrence time was from 1 d to 15 months after medication, mainly in the first 3 months (63.64%). Involving skin, respiratory system, blood system, nervous system and other body organs/systems. 33 patients improved after drug withdrawal and/or symptomatic management, and 6 patients died, indicating the potential risk of death. Conclusion Clinical workers should pay attention to the danger of adverse drug reactions caused by palbociclib, strengthen the monitoring of patients' medication, and ensure the safety of clinical medication.

R979.1

國家自然科學(xué)基金資助項目（82060674）